ClinicalTrials.gg
Not yet recruitingNCT07847671Updated Oct 8, 2026

Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC

A Phase 2 interventional study of FMT combined with QL1706 plus Bevacizumab in Advanced Hepatocellular Carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 8, 2026Eligibility revisedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular — 14 open to participants now, 14 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Carcinoma, Hepatocellular.

Planned enrollment
14th of 14
20 · median 36
Started
2026
with 2 others
Phase 2
8 of 14
8 open now
Primary completion
2029-10
later than 12 of 13 live
Registered
13th of 14
by date
Lead sponsor
1 of 14
Tianjin Medical University Cancer Institute and Hospital

Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, this one is the 14th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 13th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

14 of the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

About Iparomlimab/Tuvonralimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.

Read the detailed description

Iparomlimab and Tuvonralimab (QL1706), constitute a bifunctional antibody target both programmed death-1 and cytotoxic T lymphocyte-associated protein-4.

The purpose of this pilot study is to assess the efficacy and safety of fecal microbiota transplantation (FMT) combined with QL1706 Plus Bevacizumab as first-line treatment for advanced HCC.

The primary objective is to test the efficacy of FMT combined with QL1706 Plus Bevacizumab, as measured by objective response rate (ORR).

The secondary objectives are to assess and test the safety of FMT in combination with QL1706 Plus Bevacizumab as first-line treatment for advanced HCC as measured by Disease Control Rate (DCR), Duration of Response(DoR), Progression-Free Survival (PFS), Overall Survival (OS), and Adverse Events (AEs).

Furthermore, this study aims to investigate multi-omics prognosis prediction biomarkers and their associated mechanisms.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma (HCC)

Keywords

  • Fecal Microbiota Transplantation
  • Advanced Hepatocellular Carcinoma
  • QL1706
  • Bevacizumab
  • Iparomlimab
  • Tuvonralimab
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years.
  • Confirmed imaging or histological diagnosis of unresectable HCC.
  • Treatment-naïve unresectable or HCC.
  • BCLC Stage C.
  • A.
  • PS 0-1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an , or prior systemic therapy for advanced HCC.
  • Histologic subtypes other than hepatocellular carcinoma, including fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular cholangiocarcinoma.
  • Active or prior disease, immunodeficiency requiring systemic therapy.
  • bleeding risk, coagulopathy, or untreated high-risk esophagogastric varices.
  • Any to fecal microbiota transplantation.
  • Uncontrolled intercurrent illness, including active infection, clinically significant cardiovascular disease, central nervous system .
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    FMT combined with QL1706 plus Bevacizumab

    FMT combined with QL1706 plus Bevacizumab

    Drug: FMT combined with QL1706 plus Bevacizumab

Interventions

  • DrugFMT combined with QL1706 plus Bevacizumab

    Drug pages: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Fecal Microbiota Transplantation (FMT) capsules: Full-dose FMT (80-100g) will be administered on Days 0,28, and 49. Iparomlimab and Tuvonralimab (QL1706): QL1706 will be administered intravenously at a dose of 7.5 mg/kg, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days. Bevacizumab: Bevacizumab will be administered intravenously at a dose of 15 mg/kg body weight, with the first administration on Day 7, followed by subsequent administrations on Days 28 and 49, thereafter every 21 days.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    To assess the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to Objective Response Rate (ORR).

    Time frame: Every 9 weeks from the first dose of FMT administration until the first documented disease progression, death or study completion, up to approximately 1 year.

Secondary outcomes

  1. Disease Control Rate (DCR)

    To observe and evaluate the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for unresectable or metastatic HCC with respect to Disease Control Rate (DCR) determined by the radiologist per mRECIST v1.1 criteria.

    Time frame: Every 9 weeks from the first dose of FMT administration until the first documented disease progression, death or study completion, up to approximately 1 year.

  2. Progression-Free Survival (PFS)

    Time from the start of treatment to the first documented disease progression as determined by the radiologist per mRECIST/ RECIST v1.1 criteria or death from any cause.

    Time frame: From first study treatment until the first documented disease progression or death from any cause, whichever occurs first, up to approximately 1 year.

  3. Overall Survival (OS)

    To observe and evaluate the efficacy of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to overall survival (OS).

    Time frame: Starting from the time of treatment until death from any cause assessed from the date of the first intervention up to 24 months.

  4. Adverse events (AEs)

    To observe and evaluate the safety of FMT combined with QL1706 plus Bevacizumab as first-line treatment for metastatic HCC with respect to adverse events (AEs) AEs will be graded according to NCI-CTCAE V5.0 Safety assessments will be performed from baseline through 30 days (±7 days) after the last dose of study treatment

    Time frame: 30 days

Other outcomes

  1. Changes in patient gut microbiome composition following FMT

    Changes in patient gut microbiome will be determined by analysis of gut bacterial composition in patient stool samples at baseline and post-FMT

    Time frame: At baseline (prior to the first FMT administration), before QL1706 plus bevacizumab administration on Days 6,27, and 48, and after the third administration (approximately 9 weeks after FMT initiation).

  2. Multi-Omics prognosis biomarker Profiles

    Changes from baseline in prespecified metabolomic and immune-related biomarkers measured using metabolomic analysis and immunological assays, respectively, and their associations with clinical and associated mechanisms.

    Time frame: At baseline (prior to the first FMT administration), before QL1706 plus bevacizumab administration on Days 6,27, and 48, and after the third administration (approximately 9 weeks after FMT initiation).

07

Study locations

1 site
08

References and documents

Publications

  • Qin S, Fan J, Yang F ... LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308) Annals of Oncology, 35, S1229-S1230
  • Porcari S, Ciccarese C, Heidrich V, Rondinella D, Quaranta G, Severino A, Arduini D, Buti S, Fornarini G, Primi F, Stumbo L, Giannarelli D, Giudice GC, Damassi A, Giron Berrios JR, Puncochar M, Barbazuk TB, Piccinno G, Pinto F, Armanini F, Asnicar F, Schinzari G, Derosa L, Kroemer G, Sanguinetti M, Masucci L, Gasbarrini A, Tortora G, Cammarota G, Zitvogel L, Segata N, Iacovelli R, Ianiro G. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat Med. 2026 Apr;32(4):1316-1324. doi: 10.1038/s41591-025-04189-2. Epub 2026 Jan 28. PubMed 41606119 ↗
  • Yang Y, An Y, Dong Y, Chu Q, Wei J, Wang B, Cao H. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. EBioMedicine. 2024 Feb;100:104967. doi: 10.1016/j.ebiom.2024.104967. Epub 2024 Jan 18. PubMed 38241975 ↗
  • Lei W, Zhou K, Lei Y, Li Q, Zhu H. Gut microbiota shapes cancer immunotherapy responses. NPJ Biofilms Microbiomes. 2025 Jul 25;11(1):143. doi: 10.1038/s41522-025-00786-8. PubMed 40715107 ↗
  • Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz MB, Dubner HM, Ernst SJ, Rose A, Najjar YG, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 Feb 5;371(6529):595-602. doi: 10.1126/science.abf3363. PubMed 33542131 ↗
  • Xiao K, Li K, Xiao K, Yang J, Zhou L. Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation. Cancer Med. 2025 May;14(9):e70914. doi: 10.1002/cam4.70914. PubMed 40314129 ↗
  • Pomej K, Frick A, Scheiner B, Balcar L, Pajancic L, Klotz A, Kreuter A, Lampichler K, Regnat K, Zinober K, Trauner M, Tamandl D, Gasche C, Pinter M. Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study. PLoS One. 2025 Apr 15;20(4):e0321189. doi: 10.1371/journal.pone.0321189. eCollection 2025. PubMed 40233040 ↗
  • Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6. PubMed 38319892 ↗
  • Dai S, Chen Y, Cai W, Dong S, Zhao J, Chen L, Cheng CS. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. J Hematol Oncol. 2025 Sep 26;18(1):85. doi: 10.1186/s13045-025-01739-6. PubMed 41013723 ↗
  • 郝运, 李川, 文天夫, 彭伟. 全球及中国的肝癌流行病学特征: 基于《2022全球癌症统计报告》解读[J]. 中国普 外基础与临床杂志, 2024, 31(7): 781-789
  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PubMed 38572751 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 29, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 criteria removed
What changed in the criteria
  • RemovedInclusion Criteria:
  • RemovedMain Exclusion Criteria:
Oct 8, 2026
Contact
Study contact changed: m•••@163.com · •••3931→m•••@163.com · •••3931. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Tianjin Medical University Cancer Institute and Hospital · Tianjin, ChinaContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Oct 8, 2026
Title
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
Oct 8, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 2 criteria removed
    What changed in the criteria
    • RemovedInclusion Criteria:
    • RemovedMain Exclusion Criteria:
    Contact Study contact changed: m•••@163.com · •••3931→m•••@163.com · •••3931. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Tianjin Medical University Cancer Institute and Hospital · Tianjin, ChinaContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    Title Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847671
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Zhang Ningning, MD, PhD
Contact
mail4ningning@163.com
+8615822153931
Liu Yue, PhD
Contact
liuxiaotian116@163.com
+8615245104487
Hao Jihui, MD, PhD
principal investigator · Tianjin Medical University Cancer Institute and Hospital
Zhang Ningning, MD, PhD
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iparomlimab/Tuvonralimab · Bevacizumab

Start the discussion